CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
The new online Learning Center with new content can still be found under the “Training” folder on ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...